
David Wang, M.D., Ph.D.
Associate Professor
School Medical School
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.
View Clinical Profile
Biography
David Wang, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology.
Originally from Lexington, Kentucky, Dr. Wang holds a bachelor's degree in chemistry and biology from Asbury College in Wilmore, Kentucky. where he graduated summa cum laude. He earned his medical degree at Vanderbilt University in Nashville. He later completed his doctorate in cellular and molecular medicine at Johns Hopkins University in Baltimore. He completed internal medicine residency training at Johns Hopkins. He also completed a clinical fellowship in medical oncology and a postdoctoral fellowship in cancer biology at Sidney Kimmel Comprehensive Cancer Center.
A Diplomate of the American Board of Internal Medicine in medical oncology, Dr. Wang joined the UT Southwestern faculty in 2009 as an Assistant Professor. He was promoted to Associate Professor in 2016. He is currently the Oncology Team Lead at the UT Southwestern Esophageal Diseases Center.
Dr. Wang is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Gastroenterological Association, the Association of VA Hematology and Oncology, and the American Foregut Society.
Education
- Medical School
- Vanderbilt University School of Medicine (1999)
- Internship
- Johns Hopkins Hospital (2000), Internal Medicine
- Residency
- Johns Hopkins Hospital (2002), Internal Medicine
- Fellowship
- Johns Hopkins Hospital (2004), Medical Oncology
- Other Post Graduate Training
- Johns Hopkins University School of Medicine (2009)
- Graduate School
- Johns Hopkins University School of Medicine (2009)
- Fellowship
- Johns Hopkins Hospital (2009), Oncology
Research Interest
- Barrett's esophagus
- Esophageal cancer
- Gastric cancer
- Hedgehog signaling
- Molecularly targeted therapy
Publications
Featured Publications
- Malignant transformation of non-neoplastic Barrett’s epithelial cells through well-defined genetic manipulations.
- X Zhang, C Yu, K Wilson, HY Zhang, SD Melton, X Huo, DH Wang, RM Genta, SJ Spechler, RF Souza PLOS One September 2010 5 (9) e13093
- Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett’s Esophagus.
- X Huo, HY Zhang, XI Zhang, JP Lynch, ED Strauch, JY Wang, SD Melton, RM Genta, DH Wang, SJ Spechler, RF Souza Gastroenterology July 2010 139 (1) 194-203
- Aberrant epithelial-mesenchymal hedgehog signaling characterizes Barrett’s metaplasia.
- DH Wang, NJ Clemons, T Miyashita, AJ Dupuy, W Zhang, A Szczepny, IM Corcoran-Schwartz, DL Wilburn, EA Montgomery, JS Wang, NA Jenkins, NA Copeland, JW Harmon, WA Phillips, DN Watkins Gastroenterology May 2010 138(5) 1810-22
- Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53 dependent DNA damage responses.
- WY Chen, DH Wang, RC Yen, J Luo, W Gu, SB Baylin Cell November 2005 123 (3) 437-48
- A novel Smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-β signal transduction.
- RH Kim, D Wang, M Tsang, J Martin, C Huff, MP de Caestecker, WT Parks, X Meng, RJ Lechleider, T Wang, AB Roberts Genes and Development July 2000 14 (13) 1605-16
- Biology of Barrett’s esophagus and esophageal adenocarcinoma.
- DH Wang, RF Souza Gastrointestinal Endoscopy Clinics of North America January 2011 21 (1) 25-38
- Cancer-related inflammation and Barrett’s carcinogenesis: Interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells.
- HY Zhang, Q Zhang, X Zhang, C Yu, X Huo, E Cheng, DH Wang, SJ Spechler, RF Souza American Journal of Physiology. Gastrointestinal and Liver Physiology. 2011 (In press)
- Epigenetic inactivation of the canonical Wnt antagonist Sry-box containing gene 17 in colorectal cancer.
- W Zhang, SC Glockner, M Guo, EO Machida, DH Wang, H Easwaran, L Van Neste, JG Herman, KE Schuebel, DN Watkins, N Ahuja, SB Baylin Cancer Research April 2008 68 (8) 2764-72
- The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain.
- MP de Caestecker, T Yahata, D Wang, WT Parks, S Huang, CS Hill, T Shioda, AB Roberts, RJ Lechleider The Journal of Biological Chemistry January 2000 275 (3) 2115-22
Honors & Awards
- NCI
National Research Service Award (2006) - American Society of Clinical Oncology
Young Investigator Award (2005) - The Endocrine Society
Medical Student Achievement Award (1999) - Howard Hughes Medical Institute
Continued Fellowship for Medical Studies (1998)
Professional Associations/Affiliations
- American Association for Cancer Research
- American Gastroenterological Association
- American Society of Clinical Oncology